Oncternal Therapeutics Yönetim
Yönetim kriter kontrolleri 3/4
Oncternal Therapeutics CEO'su Jim Breitmeyer, Jun2019 tarihinde atandı, in görev süresi 5.42 yıldır. in toplam yıllık tazminatı $ 1.62M olup, şirket hissesi ve opsiyonları dahil olmak üzere 37.5% maaş ve 62.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.11% ine doğrudan sahiptir ve bu hisseler $ 38.03K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.8 yıl ve 5.4 yıldır.
Anahtar bilgiler
Jim Breitmeyer
İcra Kurulu Başkanı
US$1.6m
Toplam tazminat
| CEO maaş yüzdesi | 37.5% |
| CEO görev süresi | 5.4yrs |
| CEO sahipliği | 1.1% |
| Yönetim ortalama görev süresi | 3.8yrs |
| Yönetim Kurulu ortalama görev süresi | 5.4yrs |
Son yönetim güncellemeleri
Recent updates
We Think Some Shareholders May Hesitate To Increase Oncternal Therapeutics, Inc.'s (NASDAQ:ONCT) CEO Compensation
Jun 14
Can Oncternal Therapeutics (NASDAQ:ONCT) Afford To Invest In Growth?
Mar 03Here's Why We're A Bit Worried About Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation
Nov 06Oncternal Therapeutics (NASDAQ:ONCT) Will Have To Spend Its Cash Wisely
Jul 12We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate
Jan 12FDA clears Oncternal to proceed with dose escalation study for lymphoma car-T therapy
Oct 03Oncternal Therapeutics begins phase 3 study of zilovertamab
Sep 27Oncternal Therapeutics: Selling For Under Cash Value
Sep 02Oncternal Therapeutics GAAP EPS of -$0.23 beats by $0.02, revenue of $0.2M misses by $0.26M
Aug 09Here's Why We're Watching Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation
Aug 07Oncternal to collaborate with an AbbVie company for its phase 3 lymphoma study
Jul 14Oncternal Therapeutics: As Phase 2 Study Matures, Data Continues To Improve
Jun 07We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate
Apr 12Oncternal Therapeutics: Trading Near Cash With Impressive Results
Jan 04Oncternal Therapeutics (NASDAQ:ONCT) Is In A Good Position To Deliver On Growth Plans
Nov 09Oncternal Therapeutics: Keep An Eye On This Biopharmaceutical Company
Oct 10Oncternal: Solid Data In 2 Cancers With High Unmet Need
Jun 17We Think Oncternal Therapeutics (NASDAQ:ONCT) Can Afford To Drive Business Growth
May 05Should Oncternal Therapeutics (NASDAQ:ONCT) Be Disappointed With Their 81% Profit?
Mar 01CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$35m |
| Jun 30 2024 | n/a | n/a | -US$36m |
| Mar 31 2024 | n/a | n/a | -US$36m |
| Dec 31 2023 | US$2m | US$609k | -US$39m |
| Sep 30 2023 | n/a | n/a | -US$42m |
| Jun 30 2023 | n/a | n/a | -US$43m |
| Mar 31 2023 | n/a | n/a | -US$46m |
| Dec 31 2022 | US$2m | US$580k | -US$44m |
| Sep 30 2022 | n/a | n/a | -US$41m |
| Jun 30 2022 | n/a | n/a | -US$39m |
| Mar 31 2022 | n/a | n/a | -US$35m |
| Dec 31 2021 | US$5m | US$557k | -US$31m |
| Sep 30 2021 | n/a | n/a | -US$26m |
| Jun 30 2021 | n/a | n/a | -US$21m |
| Mar 31 2021 | n/a | n/a | -US$18m |
| Dec 31 2020 | US$780k | US$530k | -US$17m |
| Sep 30 2020 | n/a | n/a | -US$19m |
| Jun 30 2020 | n/a | n/a | -US$19m |
| Mar 31 2020 | n/a | n/a | -US$37m |
| Dec 31 2019 | US$1m | US$502k | -US$34m |
| Sep 30 2019 | n/a | n/a | -US$31m |
| Jun 30 2019 | n/a | n/a | -US$28m |
| Mar 31 2019 | n/a | n/a | -US$7m |
| Dec 31 2018 | US$518k | US$426k | -US$7m |
Tazminat ve Piyasa: Jim 'nin toplam tazminatı ($USD 1.62M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 650.80K ).
Tazminat ve Kazançlar: Jim 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Jim Breitmeyer (70 yo)
5.4yrs
Görev süresi
US$1,623,074
Tazminat
Dr. James B. Breitmeyer, also known as Jim, M.D., Ph D., served as Director of Otonomy, Inc. since June 20, 2018 until February 2023. He serves as Director of Rebalance Health, Inc. He serves as the Chief...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 5.4yrs | US$1.62m | 1.11% $ 38.0k | |
| CFO & Treasurer | 5.4yrs | US$847.91k | 0.25% $ 8.5k | |
| Chief Technical & Scientific Officer | 3.8yrs | Veri yok | 0.074% $ 2.6k | |
| General Counsel & Secretary | 3.6yrs | Veri yok | 0.14% $ 4.9k | |
| Senior Vice President of Corporate Development | 3.3yrs | Veri yok | Veri yok |
3.8yrs
Ortalama Görev Süresi
55.5yo
Ortalama Yaş
Deneyimli Yönetim: ONCT 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.8 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 5.4yrs | US$1.62m | 1.11% $ 38.0k | |
| Independent Director | 18.5yrs | US$59.80k | 0.12% $ 4.2k | |
| Independent Director | 5.4yrs | US$67.50k | 0.017% $ 579.9 | |
| Independent Director | 5.4yrs | US$67.00k | 0.044% $ 1.5k | |
| Independent Chairman of the Board | 5.4yrs | US$103.82k | 0.024% $ 828.1 | |
| Independent Director | 3.8yrs | US$61.32k | 0.00017% $ 5.8 | |
| Scientific Advisor | no data | Veri yok | Veri yok | |
| Independent Director | 5.4yrs | US$59.00k | 0.025% $ 850.4 | |
| Non-Independent Director | 5.4yrs | US$55.00k | 0.34% $ 11.6k | |
| Cell Therapy Scientific Advisory Board Member | 3yrs | Veri yok | Veri yok | |
| Prostate Cancer & Cell Therapy Scientific Advisory Board Member | 1.8yrs | US$941.21k | 0.062% $ 2.1k | |
| Cell Therapy Scientific Advisory Board Member | 3yrs | Veri yok | Veri yok |
5.4yrs
Ortalama Görev Süresi
70yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: ONCT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.4 yıldır).